Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–87 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adrenocortical Hyperfunction Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Prospective Phenotyping of Autonomous Aldosterone Secretion

NCT03484130
View directory record Official record
Conditions
Aldosterone Disorder, Adrenal Gland Disease, Blood Pressure
Interventions
Sodium loaded diet, Restricted sodium diet
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00569582
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 30, 2026, 12:51 AM EDT
Terminated Phase 2 Interventional Results available

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT00422201
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 30, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 30, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

NCT03277690
View directory record Official record
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole, Placebo
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 30, 2026, 12:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamics of Leptin and Endocrine Function

NCT00001543
View directory record Official record
Conditions
Healthy, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 12:51 AM EDT
Active, not recruiting Phase 3 Interventional

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793
View directory record Official record
Conditions
Primary Hyperaldosteronism
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 12:51 AM EDT
Completed No phase listed Observational

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism

NCT00004354
View directory record Official record
Conditions
Hyperaldosteronism
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Results available

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

NCT03718234
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders, Adrenocortical Hyperfunction, Disorders of Sex Development, Urogenital Abnormalities, Genetic Diseases, Inborn, Steroid Metabolic Diseases, Inborn, Adrenal Gland Disease, Hydrocortisone
Interventions
Subcutaneous hydrocortisone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
4 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 30, 2026, 12:51 AM EDT
Not listed No phase listed Observational

Study of Depression, Peptides, and Steroids in Cushing's Syndrome

NCT00004334
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 12:51 AM EDT
Completed No phase listed Observational

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

NCT06829537
View directory record Official record
Conditions
Resistant Hypertension, Hypercortisolism
Interventions
Not listed
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
50
States / cities
Huntington Park, California • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 12:51 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

NCT06246357
View directory record Official record
Conditions
Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
Interventions
[68Ga]Ga-PentixaFor
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 12:51 AM EDT
Completed No phase listed Observational

Adolescence, Puberty, and Emotion Regulation

NCT00016731
View directory record Official record
Conditions
Mood Disorder, Neurobehavioral Manifestation, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03697109
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 30, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 30, 2026, 12:51 AM EDT